NPS Pharmaceuticals Inc.

nps pharmaceuticals inc. - All News and Analysis

• NPS Pharmaceuticals, Inc. Q2 2008 Earnings Call Transcript

  Seeking Alpha - 2008-09-01

  Question-and-Answer SessionOperator Operator instructions And your first question comes from the line of May-Kin Ho from Goldman Sachs. Please proceed. Davis Bu – Goldman Sachs Hi, this is Davis Bu for May-Kin Ho. Unfortunately she had to step out. I have a couple of questions. First on...

  Tags: NPS Pharmaceuticals Inc.

• Phase 3 GATTEX™ Results Presented at Annual Digestive Disease Week Congress Highlight Potential New Treatment in Short Bowel Syndrome

  - 2008-05-19

  Data Show GATTEX Reduces Parenteral Nutrition Requirements for SBS Patients SAN DIEGO -- NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) today reported the presentation of Phase 3 data at the annual Digestive Disease Week DDW Congress on GATTEX[TM] teduglutide, a novel investigational compound that may reduce dependence upon parenteral nutrition PN...

  Tags: NPS Pharmaceuticals Inc., patient, U.S. Congress

• Local earnings

  - 2006-11-09

  Several companies, including some based in Utah or with ties to the state, reported quarterly financial results on Wednesday. FX Energy Salt Lake-based oil and gas company FX Energy Inc. reported a net loss of $1.7 million, or 5 cents per share, for the third quarter....

  Tags: earnings, FINANCE, FX Energy Inc., Investment, News Corp., NPS Pharmaceuticals Inc., revenue, stock

• NPS Pharmaceuticals Closes Public Offering.

  - 2000-11-16

  SALT LAKE CITY, Nov 15, 2000 NPS Pharmaceuticals, Inc. (Nasdaq: NPSP), today announced that it has closed a $168 million public offering of 4,000,000 shares of its common stock at $42 per share. The underwriters also exercised their option to purchase an additional 600,000...

  Tags: NPS Pharmaceuticals Inc., Prudential Insurance Company of America, SECURITY, solicitation, underwriter

• NPS Pharmaceuticals Prices Public Offering.

  - 2000-11-10

  SALT LAKE CITY, Nov 10, 2000 NPS Pharmaceuticals, Inc. (Nasdaq: NPSP), today announced the pricing of a public offering of 4,000,000 shares of its common stock at a price of $42.00 per share. All of the 4,000,000 shares of common stock included in the...

  Tags: Benefits, HEALTHCARE, MARKETING, NPS Pharmaceuticals Inc., Pricing, Prudential Insurance Company of America, SOFTWARE

• NPS Pharmaceuticals Files Registration Statement for Common Stock Offering.

  - 2000-10-16

  SALT LAKE CITY, Oct 13, 2000 (Please disregard the previous press release dated September 6, 2000 concerning the Company's filing of a registration statement for a common stock offering. The September 6, 2000 press release is replaced in its entirety by the following information.)...

  Tags: Company, NPS Pharmaceuticals Inc., SEC, SECURITY

• NPS Pharmaceuticals Files Registration Statement For Common Stock Offering.

  - 2000-09-07

  SALT LAKE CITY, Sep 06, 2000 NPS Pharmaceuticals, Inc. (Nasdaq: NPSP; Toronto: NX) announced today that it has filed a registration statement with the Securities and Exchange Commission relating to a proposed public offering of 3,000,000 shares of NPS common stock. The Company will...

  Tags: Company, INTERNET, NPS Pharmaceuticals Inc., SEC, SECURITY, Toronto

Additional Resources

• NPS Pharmaceuticals Initiates Phase 3 'REPLACE' Study of NPSP558 in Hypoparathyroidism

  - 2008-12-22

  BEDMINSTER, N.J. -- NPS Pharmaceuticals (NASDAQ: NPSP), a specialty pharmaceutical company focused on developing therapeutics for rare gastrointestinal and endocrine disorders, today announced it has begun patient enrollment in a Phase 3 registration study, known as REPLACE, evaluating NPSP558 for the treatment of adults with hypoparathyroidism. NPSP558 is the company's...

• NPS Pharmaceuticals Initiates Phase 3 'STEPS' Study to Confirm GATTEX™ Reduces Parenteral Nutrition Dependence in Short Bowel Syndrome

  - 2008-12-02

  BEDMINSTER, N.J. -- NPS Pharmaceuticals (NASDAQ: NPSP), a specialty pharmaceutical company focused on developing therapeutics for rare gastrointestinal and endocrine disorders, today announced that patient enrollment has begun in a Phase 3 registrational study to confirm previously reported data that demonstrated GATTEX[TM] teduglutide was well tolerated and reduced parenteral nutrition...

• NPS Pharmaceuticals to Present at Piper Jaffray Health Care Conference

  - 2008-11-21

  BEDMINSTER, N.J. -- NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) announced today that Francois Nader, M.D., president and chief executive officer, is scheduled to present at the 20th Annual Piper Jaffray Health Care Conference in New York on Wednesday, December 3, 2008 at 12:00 p.m. ET. The presentation will be available as...

• NPS Pharmaceuticals to Present at Rodman & Renshaw Healthcare Conference

  - 2008-11-06

  BEDMINSTER, N.J. -- NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) reported today that Francois Nader, M.D., president and chief executive officer, is scheduled to present at the Rodman & Renshaw 10th Annual Healthcare Conference in New York on Tuesday, November 11, 2008 at 4:30 p.m. ET. The presentation will be available as...

• NPS Pharmaceuticals Reports Third Quarter 2008 Financial Results and Business Update

  - 2008-11-05

  Management Improves 2008 Cash Burn Guidance IRB Approval Process Underway for Two Registration Studies Conference Call Today at 8:00 AM ET BEDMINSTER, N.J. -- NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a specialty pharmaceutical company focused on developing therapeutics for rare gastrointestinal and endocrine disorders, today...

• NPS Pharmaceuticals to Report Third Quarter 2008 Financial Results

  - 2008-10-31

  BEDMINSTER, N.J. -- NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) announced today that it will report its third quarter 2008 financial results on Wednesday, November 5, 2008 before the market open. The announcement will be followed by a conference call and webcast at 8:00 am Eastern Time. To participate in...

• NPS Pharmaceuticals Announces Multiple GATTEX™ Data Presentations at 16th United European Gastroenterology Week Meeting

  - 2008-10-15

  BEDMINSTER, N.J. -- NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) today announced that four abstracts summarizing data from the Company's Phase 3 studies of GATTEX[TM] teduglutide in patients with short bowel syndrome SBS were selected for oral presentations at the 16th United European Gastroenterology Week UEGW meeting in Vienna, Austria, October 18-22,...

• One Year of GATTEX™ Therapy Safely Reduces Parenteral Nutrition Dependence for Patients with Short Bowel Syndrome

  - 2008-10-08

  -- Results Presented at American College of Gastroenterology Annual Meeting Show Majority of Responders Continued to Benefit from GATTEX in Phase 3-Extension Study -- ORLANDO, Fla. -- NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) today presented positive one-year data from a Phase 3-extension study of GATTEX[TM] teduglutide, an investigational product...

• GATTEX™ Abstracts to be Presented at ACG Meeting; 52-Week Data from Phase 3 Clinical Trial Scheduled for Plenary Session

  - 2008-09-23

  BEDMINSTER, N.J. -- NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) today reported that three abstracts summarizing data from the company's Phase 3 studies of GATTEX[TM] teduglutide in patients with short bowel syndrome SBS were accepted for presentation at the American College of Gastroenterology ACG Annual Scientific Meeting and Postgraduate Course in Orlando,...

• Positive Interim Data from Phase 2 Study of NPSP558 for Hypoparathyroidism Reported at ASBMR Annual Meeting

  - 2008-09-15

  Positive Effects on Skeletal Properties Support Further Clinical Testing BEDMINSTER, N.J. -- At the 30th Annual Meeting of the American Society for Bone and Mineral Research ASBMR, positive interim data were presented from an investigator-initiated Phase 2 proof-of-concept study of NPSP558, the proprietary recombinant full-length human parathyroid hormone...

• NPS Pharmaceuticals to Report GATTEX™ Data at ESPEN, ACG, UEGW Congresses

  - 2008-09-11

  BEDMINSTER, N.J. -- NPS Pharmaceuticals (Nasdaq: NPSP) today reported that data from clinical studies of GATTEX[TM] teduglutide in intestinal failure associated with short bowel syndrome will be presented at upcoming medical meetings. At the 30th Congress of the European Society for Clinical Nutrition and Metabolism ESPEN taking place...

• NPS Pharmaceuticals Reports Second Quarter Financial Results

  - 2008-08-07

  BEDMINSTER, N.J. -- NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) today reported its financial results for the second quarter of 2008. Revenues were $27.0 million for the second quarter of 2008, as compared to $13.1 million for the second quarter of 2007. Operating expenses decreased to $10.6 million for the second quarter...

• NPS Pharmaceuticals to Report Second Quarter 2008 Financial Results

  - 2008-07-29

  BEDMINSTER, N.J. -- NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) announced today that it will report its second quarter 2008 financial results on Thursday, August 7, 2008 post-market. The announcement will be followed by a conference call and webcast at 4:30 pm Eastern Time. To participate in the conference call,...

• Incorporated: 1986
• CEO: Dr. Francois Nader M.D.